Atreca to Present at Upcoming Investor Conferences

SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology firm targeted on growing novel therapeutics generated by means of a singular discovery platform based mostly on interrogation of the energetic human immune response, at this time introduced that it’ll current at the next upcoming investor conferences:

H.C. Wainwright 24^th Annual Global Investment Conference
September 12-14, 2022
Presentation: 2:30 pm EDT, September 13, 2022

Baird Global Healthcare Conference
September 13-14, 2022
Presentation: 2:00 pm EDT, September 14, 2022

A stay webcast of the H.C. Wainwright presentation could be accessed by means of the Events & Presentations part of the Company’s web site at http://ir.atreca.com. An archived replay of the presentation shall be obtainable on the Company’s web site for 30 days following the stay broadcast.

About Atreca, Inc.
Atreca is a biopharmaceutical firm growing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca’s platform permits entry to an unexplored panorama in oncology by means of the identification of distinctive antibody-target pairs generated by the human immune system throughout an energetic immune response in opposition to tumors. These antibodies present the idea for first-in-class therapeutic candidates, equivalent to our lead product candidate ATRC-101, a monoclonal antibody focusing on a novel ribonucleoprotein complicated, in addition to ATRC-301, an antibody drug conjugate focusing on a novel epitope on EphA2. A Phase 1b research evaluating ATRC-101 in a number of stable tumor cancers is presently enrolling sufferers, and ATRC-301 is in IND-enabling research. For extra info on Atreca, please go to www.atreca.com.

Forward-Looking Statements

This launch accommodates statements relating to issues that aren’t historic details which might be “forward-looking statements” inside the that means of the Private Securities Litigation Reform Act of 1995. These forward-looking statements embody, however are usually not restricted to, statements relating to our technique and future plans, together with statements relating to the event of ATRC-101, ATRC-301, and our preclinical and scientific plans and the timing thereof. Our precise outcomes might differ materially from these indicated in these forward-looking statements due to dangers and uncertainties associated to the initiation, timing, progress and outcomes of our analysis and improvement packages, preclinical research, scientific trials, regulatory submissions, and different issues which might be described in our most up-to-date Annual Report on Form 10-Ok and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and obtainable on the SEC’s web site at www.sec.gov, together with the chance elements set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which converse solely as of the date of this launch, and we undertake no obligation to replace any forward-looking assertion on this press launch, besides as required by legislation.

Contacts

Atreca, Inc.
Herb Cross
Chief Financial Officer
[email protected]

Investors:
Alex Gray, 650-779-9251
[email protected]

Media:
Julia Fuller, 858-692-2001
[email protected]